Holding website  

  • About Us
    • What we do
      • Strategic Approach
    • Management Team
    • Collaboration & Partnering
    • Investors
    • Careers
      • Open Positions
        • Head of Medical Affairs
    • Privacy
  • APR Products
    • Prescription Healthcare Products
      • PKU GOLIKE® Family
      • Nexodyn® – Advanced Wound Care
        • Tehclo Technology
      • Diclofenac Immediate Release
        • Immediate Release Technology
        • Diclofenac 50 mg products
      • Ondansetron ODF
        • ODF Technology
        • Ondansetron ODF products
      • APR TD011 – Epidermolysis Bullosa
        • Tehclo Technology
      • APR TD012 – Hailey Hailey Disease
        • Tehclo Technology
      • APR 1204 – Ocular Surface Diseases
        • Tehclo Technology
      • Exelya®
        • Exelya®
        • Tehclo Technology
    • Consumer Healthcare Products
      • Acute Pain
        • Diclofenac 25 mg products
      • Healthy Aging – SwitzAge™
      • Pediatric
        • Halykoo
    • Therapeutical Areas
      • Inherited Metabolic Disorders
        • What is PKU (Phenylketonuria)?
      • Advanced Wound Care
        • Unmet Medical Need
      • Cancer Supportive Care
        • Nausea and vomiting
        • Oncodermatology
      • CNS (migraine)
      • Rare Dermatological Diseases
        • Epidermolysis Bullosa
        • Hailey Hailey Disease
      • Eye laser surgery
    • Pipeline
  • Our Services
    • Solid Dosage Forms
      • Oral Pharmaceuticals
        • Integrated project development
        • Project design planning
      • Oral Nutraceuticals
        • Integrated project development
        • Project design planning
      • Oral Medical Devices
        • Integrated project development
        • Project design planning
    • Non-Solid Dosage Forms
      • Topical Pharmaceuticals
        • Integrated project development
        • Project design planning
      • Topical Dermocosmetics
        • Integrated project development
        • Project design planning
      • Topical Medical Devices
        • Integrated project development
        • Project design planning
    • Analytical Services
    • Certifications
  • Media
    • Presentations
    • Press Releases
  • Contacts
    • Location
    • Vigilance
    • APR LAB

Discover who we are and our partners global network, as well as learn more about our people.

Learn more about our products and how they provide innovative solutions for patiens' unmet needs.

Discover our capabilities in project design services.

Find information such as website news, press releases and event presentations.

Get in touch with us to set up a meeting or propose your cooperation.

 
Vigilance

Holding website  

  • About Us
    • What we do
      • Strategic Approach
    • Management Team
    • Collaboration & Partnering
    • Investors
    • Careers
      • Open Positions
        • Head of Medical Affairs
    • Privacy
  • APR Products
    • Prescription Healthcare Products
      • PKU GOLIKE® Family
      • Nexodyn® – Advanced Wound Care
        • Tehclo Technology
      • Diclofenac Immediate Release
        • Immediate Release Technology
        • Diclofenac 50 mg products
      • Ondansetron ODF
        • ODF Technology
        • Ondansetron ODF products
      • APR TD011 – Epidermolysis Bullosa
        • Tehclo Technology
      • APR TD012 – Hailey Hailey Disease
        • Tehclo Technology
      • APR 1204 – Ocular Surface Diseases
        • Tehclo Technology
      • Exelya®
        • Exelya®
        • Tehclo Technology
    • Consumer Healthcare Products
      • Acute Pain
        • Diclofenac 25 mg products
      • Healthy Aging – SwitzAge™
      • Pediatric
        • Halykoo
    • Therapeutical Areas
      • Inherited Metabolic Disorders
        • What is PKU (Phenylketonuria)?
      • Advanced Wound Care
        • Unmet Medical Need
      • Cancer Supportive Care
        • Nausea and vomiting
        • Oncodermatology
      • CNS (migraine)
      • Rare Dermatological Diseases
        • Epidermolysis Bullosa
        • Hailey Hailey Disease
      • Eye laser surgery
    • Pipeline
  • Our Services
    • Solid Dosage Forms
      • Oral Pharmaceuticals
        • Integrated project development
        • Project design planning
      • Oral Nutraceuticals
        • Integrated project development
        • Project design planning
      • Oral Medical Devices
        • Integrated project development
        • Project design planning
    • Non-Solid Dosage Forms
      • Topical Pharmaceuticals
        • Integrated project development
        • Project design planning
      • Topical Dermocosmetics
        • Integrated project development
        • Project design planning
      • Topical Medical Devices
        • Integrated project development
        • Project design planning
    • Analytical Services
    • Certifications
  • Media
    • Presentations
    • Press Releases
  • Contacts
    • Location
    • Vigilance
    • APR LAB

VIGILANCE

Se avete osservato problemi in seguito all’uso dei nostri prodotti, componete il numero
0041 79 9166232.

Informativa ai sensi:
  • dell’art. 14 della Legge federale sulla protezione dei dati del 19 giugno 1992
    https://www.admin.ch/opc/it/classified-compilation/19920153/index.html
  • Regolamento Generale sulla Protezione dei dati (Regolamento EU n. 679/2016)
    https://www.garanteprivacy.it/il-testo-del-regolamento

If you have experienced any problem following the use of our products, please dial number
0041 79 9166232.

Information pursuant to:
  • art. 14 of Federal Act on Data Protection of 19 June 1992
    https://www.admin.ch/opc/it/classified-compilation/19920153/index.html
  • General Data Protection Regulation came into effect on May 25th, 2018 (GDPR)
    https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex:32016R0679

Cosa fare se avete osservato problemi in seguito all’uso dei nostri prodotti?

Come prima cosa, è consigliabile consultare immediatamente un medico.
Se avete usato e/o assunto un prodotto di Applied Pharma Research s.a. (di seguito “APR”) e intendete segnalare un problema al responsabile APR per la vigilanza, potete farlo scrivendo qui

What should you do if you discover a problem after using one of our products?

First of all, we recommend that you see a doctor immediately.
If you have used and/or ingested an Applied Pharma Research s.a. (hereinafter “APR”) product and intend to report a problem to the APR Head of Vigilance, you can do this by writing them here

Que faire si vous constatez un problème après avoir utilisé l’un de nos produits ?

Avant toute chose, nous vous conseillons de consulter immédiatement un médecin.
Si vous avez utilisé et/ou pris un produit d’Applied Pharma Research s.a. (désigné ci-après comme « APR ») et souhaitez signaler un problème au responsable du département Vigilance d’APR, vous pouvez envoyer un courrier à l’adresse suivante

Was Sie tun sollten, wenn es nach Anwendung eines unserer Produkte zu Problemen kommt

Als erstes sollten Sie unverzüglich einen Arzt aufsuchen.
Wenn Sie eines der Produkte von Applied Pharma Research s.a. (im Weiteren „APR“ genannt) angewendet oder eingenommen haben und dem Leiter der Produktüberwachung von APR ein Problem melden möchten, tun Sie das bitte hier

Qué debe hacer si descubre un problema tras utilizar uno de nuestros productos

Antes de nada, le recomendamos que acuda a un médico de inmediato.
Si ha utilizado y/o ingerido un producto de Applied Pharma Research S.A. (“APR” de aquí en adelante) y tiene pensado notificar el problema a los responsables de vigilancia de APR, puede escribirles aquí para hacerlo.

如果您在使用我们的产品后发现有问题,应该怎么办?

首先,我们建议您立即就医。 如果您已使用和/或服用Applied Pharma Research s.a. (以下简称“APR”)的产品并打算向警戒的APR的总部报告一个问题,您可以在 这里 给他们编写信息
Location APR LAB
APR 2015 all rights reserved | About us | APR Products | Our services | News & Events | Contact | Privacy policy | Cookie policy | Sitemap